Tranexamic acid for preventing postpartum haemorrhage.

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Evidence-Based Medicine

Background:

• Postpartum hemorrhage (PPH) is a significant complication of childbirth.
• Effective and safe prevention strategies for PPH are crucial.
• Tranexamic acid (TA), an antifibrinolytic, is a potential agent for PPH prevention.

Purpose of the Study:

• To evaluate the efficacy and safety of tranexamic acid (TA) in preventing PPH.
• To compare TA with placebo or no treatment, and with uterotonic agents.
• To assess TA's effectiveness in both vaginal births and Cesarean sections (CS).

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Searched Cochrane Pregnancy and Childbirth Group's Trials Register and reference lists.
• Included 12 RCTs with 3285 women undergoing elective CS or spontaneous birth.

Main Results:

• TA significantly reduced postpartum blood loss exceeding 400 mL, 500 mL, and 1000 mL.
• TA decreased the incidence of blood loss >1000 mL in CS but not vaginal births.
• Mean blood loss was lower with TA; additional interventions and transfusions were less frequent.
• Minor side effects like nausea and dizziness were more common with TA.

Conclusions:

• Tranexamic acid (TA), when used with uterotonics, effectively reduces postpartum blood loss and prevents PPH.
• TA decreases the need for blood transfusions in women after vaginal birth and CS.
• Further research is needed on TA's effects in high-risk women and on severe outcomes like thromboembolism and mortality.